Glofitamab plus CAR-T for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma that tests positive for CD19 and CD20. This includes common forms like diffuse large B-cell lymphoma (DLBCL) and others.
- Your lymphoma must have come back or not responded after at least one prior treatment, and that prior treatment should have included certain chemotherapy and an anti-CD20 antibody.
- You need to have at least one high-risk feature: lymphoma outside the lymph nodes, a tumor larger than 4 cm, or a TP53 gene change.
- The lymphoma must not be in your brain or spinal cord.
- You should be in fairly good overall health, with a performance status of 0, 1, or 2 (meaning you can do daily activities with little or no help), and your blood counts and organ function (kidneys, liver, lungs, heart) must be within acceptable ranges.
- You cannot have certain active infections, a history of stem cell or organ transplant, significant heart disease, or active other cancers (except for some early-stage or skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This trial tests a new approach to treating aggressive B-cell lymphomas that have returned or didn't respond to initial chemotherapy. It combines a drug called glofitamab with CAR-T cell therapy (immune cells engineered in the lab to fight cancer) to see if it improves outcomes for patients who are candidates for this advanced treatment.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.